[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"depressive-symptoms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:depressive-symptoms":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,87,0,25,[9,48,99,126,153,176,199,220,251,275,301,319,355,383,409,444,464,491,520,540,561,584,608,633,655],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640953","phase-2-jak-signaling-in-depression-and-cognition-in-male-football-players-100640953",false,"NCT07608796","JAK Signaling in Depression and Cognition in Male Football Players","JAK DC in Play","Inclusion Criteria:\n\n* willing and able to give written informed consent\n* males\n* playing tackle football for at least 11 years\n* 30-55 years of age\n* Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V\n* score of \\>10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry\n* off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)\n* CRP ≥3 mg\u002FL\n* PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2\n\nExclusion Criteria:\n\n* current or history of past autoimmune disorder\n* history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection\n* history of any type of cancer requiring treatment with more than minor surgery\n* unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)\n* significant hematological abnormalities at screening (ANC \\\u003C 1500, Hgb\\\u003C10, platelet\\\u003C 100,000)\n* history of progressive multifocal leukoencephalopathy\n* history of deep venous thrombosis\n* history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)\n* major surgery within 6 months before screening, or will require major surgery during the study\n* current or recent (\\\u003C4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection\n* symptomatic herpes zoster infection at or within 12 weeks of study start\n* history of disseminated\u002Fcomplicated herpes zoster (for example, ophthalmic zoster or CNS involvement)\n* cirrhosis of the liver from any cause\n* Additional exclusion criteria apply",true,"MALE","30 Years","55 Years",{"count":22,"type":23},30,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.",[29,30],"Depressive Symptoms","Cognitive Symptom",[32,33,34],"Football player","Inflammation","NFL","NOT_YET_RECRUITING","2026-08-18",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":23},"2026-09",{"date":43,"type":23},"2027-10",{"name":45,"class":46},"Emory University","OTHER",3,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":82,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":98},"100551600","natural-history-of-depression-bipolar-disorder-and-suicide-risk-100551600","NCT06462196","Natural History of Depression, Bipolar Disorder and Suicide Risk","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers\n* Age 18 years or older\n* Able to provide informed consent\n* Able to read and write English\n\nEXCLUSION CRITERIA:\n\n* Unstable medical conditions in the opinion of the investigator that would preclude participation in outpatient or inpatient treatment.\n* Pregnancy\n* Participation in the Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers, as a healthy volunteer.\n* Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to consent and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to enrolling in the study. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician.","ALL","18 Years","120 Years",{"count":58,"type":23},500,"OBSERVATIONAL","Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide.\n\nPeople 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254.\n\nThis study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time.\n\nParticipants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.",[62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,29,79,80,81],"Behavioral Symptoms","Suicide","Self-Injurious Behavior","Sensory System Agents","Analgesics","Peripheral Nervous System Agents","Physiological Effects of Drugs","Anesthetics, Dissociative","Anesthetics, General","Anesthetics","Central Nervous System Depressants","Excitatory Amino Acid Antagonists","Excitatory Amino Acid Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Ketamine","Depression, Unipolar","Treatment Resistant Depression","Major Depressive Disorder","Depression, Bipolar",[83,63,80,84,85,86,79],"Neurobiology","Bipolar Disorder","Biomarkers","Suicide Risk","RECRUITING","2026-08-13",{"date":90,"type":39},"2026-08-14",{"date":92,"type":39},"2024-09-09",{"date":94,"type":23},"2030-06-01",{"name":96,"class":97},"National Institute of Mental Health (NIMH)","NIH",1,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":24,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":98},"100651953","phase-2-electrophysiologic-mechanisms-of-ketamine-antidepressant-response-100651953","NCT07768618","Electrophysiologic Mechanisms of Ketamine Antidepressant Response","Electrophysiologic Dynamics of Depression and Antidepressant Response in Epilepsy","Ketamine-sEEG","Inclusion Criteria:\n\n* Admitted to the Emory EMU for clinically indicated sEEG monitoring for epilepsy.\n* At least mild depressive symptoms at baseline, defined as MADRS ≥7 or BDI-II ≥14.\n* Electrode coverage that includes midline regions sufficient for enrollment and analyses.\n* Ability to provide informed consent and to complete bedside tasks\u002Fquestionnaires in English.\n* Expected to remain under inpatient monitoring through the planned \\~24-hour post-infusion follow-up unless clinical needs dictate otherwise.\n\nExclusion Criteria:\n\n* Documented IQ \\\u003C70, intellectual disability, severe cognitive impairment, delirium, severe aphasia, or other condition that prevents valid consent or task participation.\n* Current or past schizophrenia-spectrum disorder or other psychotic disorder.\n* Current manic\u002Fhypomanic episode or bipolar-spectrum illness judged by study psychiatrist\u002Finvestigator to increase risk or confound interpretation.\n* Active alcohol or substance abuse\u002Fdependence within the past 3 months.\n* Imminent suicide risk or active suicidal intent requiring urgent intervention as determined by clinical assessment. Passive ideation without imminent intent may be considered on a case-by-case basis with psychiatric approval and enhanced monitoring.\n* Contraindication to subanesthetic ketamine, including uncontrolled hypertension, unstable cardiovascular disease, aneurysm\u002Fvascular malformation or similar condition conferring unacceptable risk, pregnancy, breastfeeding, or other clinically significant medical instability.\n* Clinical team determination that ketamine administration or study timing would interfere with epilepsy care or perioperative management.\n* Sedative or other medication exposure at a level that, in the judgment of the clinical team, precludes safe ketamine administration or reliable behavioral assessment (participant may be deferred rather than permanently excluded if the issue resolves).",{"count":108,"type":23},37,[26],"This study aims to identify electrophysiologic biomarkers associated with antidepressant response to ketamine in adults with epilepsy undergoing clinically indicated stereo-electroencephalography (sEEG) monitoring who have at least mild depressive symptoms.\n\nParticipants will receive a single subanesthetic intravenous ketamine infusion (0.5 mg\u002Fkg over 40 minutes) during their Epilepsy Monitoring Unit admission. Intracranial neural recordings and behavioral assessments will be collected before and approximately 24 hours after infusion to examine changes in neural circuits associated with rumination and anhedonia.",[112,29],"Epilepsy",[114,112,77,115,116,117],"Depression","Stereo-electroencephalography","Antidepressant Response","Electrophysiologic Biomarker","2026-08-12",{"date":120,"type":39},"2026-08-17",{"date":122,"type":23},"2026-12",{"date":124,"type":23},"2031-12",{"name":45,"class":46},{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":24,"phases":135,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":98},"100650942","dexmedetomidine-esketamine-combination-on-depression-and-anxiety-after-laparoscopic-ureteral-reconstruction-100650942","NCT07753772","Dexmedetomidine-Esketamine Combination on Depression and Anxiety After Laparoscopic Ureteral Reconstruction","Perioperative Use of Dexmedetomidine-esketamine Combination on Depression and Anxiety in Patients Undergoing Laparoscopic Ureteral Reconstruction: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged ≥ 18 years;\n2. Diagnosed with ureteral stricture and scheduled for elective laparoscopic ureteral reconstruction under general anesthesia;\n3. Requiring patient-controlled intravenous analgesia after surgery.\n\nExclusion Criteria:\n\n1. Preoperative inability to communicate due to coma, delirium, severe dementia, or language barrier;\n2. History of schizophrenia, epilepsy, Parkinson's disease, or myasthenia gravis;\n3. Presence of preexisting left ventricular ejection fraction (LVEF) \\\u003C 30%, sick sinus syndrome, severe sinus bradycardia (heart rate \\\u003C 50 beats\u002Fmin), or atrioventricular block above grade II without pacemaker implanted;\n4. Uncontrolled hyperthyroidism or history of pheochromocytoma;\n5. Severe hepatic insufficiency (Child-Pugh Class C), severe renal insufficiency (required preoperative dialysis), or American Society of Anesthesiologists (ASA) physical status classification ≥ IV;\n6. Allergy to dexmedetomidine and\u002For esketamine;\n7. Other conditions deemed unsuitable for study participation by the investigators.",{"count":134,"type":23},658,[136],"PHASE4","Anxiety and depressive symptoms are prevalent in patients undergoing surgical repair for ureteral stricture, driven by chronic pain, renal function concerns, and surgical uncertainty. Dexmedetomidine has anxiolytic and antidepressant effects but may increase bradycardia and hypotension; esketamine provides rapid antidepressant efficacy but may cause psychiatric side effects. Preliminary studies showed that combined use of low-dose dexmedetomidine and esketamine reduced the prevalence of postoperative depressive symptoms without increasing adverse events. This study is designed to test the hypothesis that perioperative use of low-dose dexmedetomidine-esketamine combination may relieve postoperative depressive symptoms and anxiety in patients undergoing laparoscopic ureteral reconstruction.",[139,140,141,29,142],"Ureteral Stricture","Dexmedetomidine","Esketamine","Anxiety",[144,140,141,145,142],"Laparoscopic ureteral reconstruction","Depressive symptoms",{"date":90,"type":39},{"date":148,"type":23},"2026-08",{"date":150,"type":23},"2029-08",{"name":152,"class":46},"Peking University First Hospital",{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":24,"phases":163,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":170,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":98},"100531932","the-oh-happy-day-class---digital-connections-ohdc-dc-a-pilot-study-100531932","NCT06206226","The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study","The Oh Happy Day Class - Digital Connections (OHDC-DC): an Exploratory Pilot Study","OHDC-DC","Inclusion Criteria:\n\n* African-American\n* Age 18 and older\n* Experiencing depression (as evidenced by a score of 5 or higher on the PHQ-9)\n* Own a mobile phone\n\nExclusion Criteria:\n\n* Individuals who are currently receiving psychotherapy\n* Individuals who are presently experiencing suicidal ideation\n* Individuals who started psychotropic medication less than three months prior to the start of the OHDC will be excluded from the study\n* Participants scoring 25 or higher on the PHQ-9 will be screened out",{"count":162,"type":23},8,[164],"NA","The goal of this clinical trial is to see if a mobile phone app can deliver depression treatment to African Americans who are depressed. The main question it aims to answer is if this treatment is effective in reducing symptoms of depression.\n\nParticipants will attend six 90-minute weekly classes via an app on their phone, and will be asked to complete surveys every week. Participants can expect to be in the study for four months.",[114,167,29],"Depressive Disorder",[169],"African American",{"date":90,"type":39},{"date":148,"type":23},{"date":173,"type":23},"2027-02",{"name":175,"class":46},"University of Wisconsin, Madison",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":17,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":24,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100641502","metformin-as-adjunct-therapy-in-depression-obesity-comorbidity-clinical-and-genetic-evaluation-100641502","NCT07654179","Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation","Efficacy of Metformin With Antidepressant Medication as Adjunct Therapy in Depression-obesity Ccomorbidity and Ssociation With NEGR1\u002FRPL31P12 Variants Based on Genotyping","INCLUSION CRITERIA Group I: Normal Controls Group II: Depression Group III: Obesity\n\nGroup IV and V:\n\n* Age ≥ 18 years\n* Both males and females\n* Recurrent depressive disorder (6A71) according to ICD-11,\n* Asian cut off: Obese and overweight (BMI \\\u003C 23)\n* BDI score ≥ 13 or PHQ score ≥ 4\n* Either medication-naïve or medication-free for at least 2 weeks before enrollment, or the patient did not take antidepressants during the last 7 days before study entry (discontinuation of effective medication to enable study participation is prohibited)\n* In case of non-psychotropic medication: The patient received stable pharmacological medication for at least 14 days before study entry (any changes in medication dose or frequency of therapy must be answered with no)\n\nEXCLUSION CRITERIA Groups I-III: Negative Controls (Normal: no depression and Obesity for SNP comparison only)\n\n* Age less than 18\n* Dementia\u002F Mentally impaired who can not fill self report performas for inclusion criteria\n\nGroup IV: Positive Control (RCT patients)\n\n* Patients with comorbid conditions (HTN, CKD) if taking any drug for that condition.\n* The patient is not an employee of the investigator study site, or a family member of the employees or the investigator, or otherwise dependent on the sponsor, the investigator, or the investigator study site.\n* The patient did not participate in other interventional trials during the 6 months before and at the time of this trial. The patient does not have a history of non-response to antidepressants included in the study.\n* The patient has not given birth within the 6 months before study entry and is not breastfeeding\n* The patient did not receive treatment with ketamine, irreversible MAO inhibitor (e.g. tranylcypromine), electroconvulsive therapy (ECT) or other stimulatory treatments in the index episode.\n* The patient is not diagnosed with dementia and does not have moderate or severe impairment of general cognitive function according to clinical impression.\n* The patient does not meet the criteria for alcohol use disorder (DSM-5: 303.90; ICD-10: F10.20) or substance use disorder (DSM-5: 304; ICD-10: F11.20 - F19.20) in DSM-5, and a urine\u002Fserum drug screening is negative (except for benzodiazepines and opiates).\n* The patient does not have:\n\n  * A known allergy or contraindication against antidepressants included in the study\n  * History of suicidal tendencies\n  * Uncontrolled hepatic disorder, renal or cardiovascular disease\n  * DM\n  * Untreated hypothyroidism\n  * History of myocardial infarction or stroke\n  * Symptomatic peripheral arterial disease\n  * Monogenic familial hypercholesterolemia",{"count":184,"type":23},200,[164],"The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy. NEGR1\u002FRPL31P12 gene polymorphisms may influence the comparative efficacy of antidepressant monotherapy versus combination therapy (antidepressant + metformin) in Pakistani patients. Patients with certain variants may respond better or worse to antidepressants and may have different weight outcomes.",[114,167,188,29],"Overweight or Obesity","2026-08-04",{"date":191,"type":39},"2026-08-07",{"date":193,"type":39},"2026-06-17",{"date":195,"type":23},"2027-06-11",{"name":197,"class":46},"Riphah International University",2,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":17,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":207,"briefSummary":208,"conditions":209,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":98},"100482869","using-machine-learning-to-optimize-user-engagement-and-clinical-response-to-digital-mental-health-interventions-100482869","NCT05567640","Using Machine Learning to Optimize User Engagement and Clinical Response to Digital Mental Health Interventions","Inclusion Criteria:\n\n* English-speaking adults\n* Ages 18 or older\n* Have a device that can connect to the internet.",{"count":206,"type":23},1800,[164],"Digital mental health interventions are a cost-effective and efficient approach to expanding the accessibility and impact of psychological treatments; however, little guidance exists for selecting the most effective program for a given individual. In the proposed study, decision rules will develop for selecting the digital program that is most likely to be the optimal intervention for each user. These treatment recommendations can be implemented in the context of large healthcare delivery systems to improve the delivery of digital mental health interventions at scale.\n\nThe overarching aim of the current study is to better understand for whom and how leading digital interventions work in a large healthcare setting. The study builds on the existing literature and follows expert recommendations by using machine learning (ML) methods to develop precision treatment rules (PTRs) for three leading digital interventions for emotional disorders (e.g., anxiety, depression, and related mental health disorders). Specifically, ML methods will be used to develop PTRs to optimize clinical outcomes and associated intervention engagement. This study will leverage a unique partnership between Boston University (BU), SilverCloud Health (SC)--a leading provider of digital mental health care--and Kaiser Permanente (KP)--one of America's leading health care providers.\n\nA clinical trial (RCT) will be conducted to evaluate the relative effectiveness of three distinct empirically supported digital mental health interventions (from SC's existing library of programs) in a sample recruited from KP primary care and other clinical settings. Data from this trial will be used to develop theoretically and empirically informed, reliable selection algorithms for managing treatment delivery decisions. Algorithms will be validated in a separate \"holdout\" dataset by examining whether allocation to predicted optimal treatment is associated with superior outcomes compared to allocation to a non-optimal treatment. The role of user engagement will be determined, and other mechanisms in treatment outcome.",[210,29],"Anxiety Disorders and Symptoms","2026-07-30",{"date":213,"type":39},"2026-07-31",{"date":215,"type":39},"2023-04-12",{"date":217,"type":23},"2027-07",{"name":219,"class":46},"Boston University Charles River Campus",{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":17,"sex":54,"minAge":55,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":98},"100649756","effects-of-exercise-intervention-on-sleep-quality-and-emotional-problems-in-college-students-with-depressive-symptoms-100649756","NCT07738809","Effects of Exercise Intervention on Sleep Quality and Emotional Problems in College Students With Depressive Symptoms","Effects of Exercise Intervention on Sleep Quality, Emotional Problems, and Neuroelectrophysiological Mechanisms in College Students With Depressive Symptoms","Inclusion Criteria:\n\n* • Aged 18-23 years.\n\n  * Right-handed.\n  * Non-physical education major.\n  * No history of psychiatric disorders and no current or previous use of psychotropic medications, hypnotics, or other medications affecting the central nervous system.\n  * No history of traumatic brain injury or chronic physical diseases.\n  * No contraindications to physical exercise.\n  * Participants with a Beck Depression Inventory-II (BDI-II) score \\>13 will be classified as having depressive symptoms, whereas participants with a BDI-II score ≤13 will be classified as having no depressive symptoms.\n\nExclusion Criteria:\n\n* Vigorous physical exercise, alcohol consumption, caffeine intake, or other stimulating behaviors within 24 hours before testing.\n\n  * Withdrawal from the study before completion of EEG recording or behavioral task assessments.\n  * Participants will be excluded from the final analysis if they fail to complete the required questionnaires or if the collected data do not meet predefined quality control criteria.","23 Years",{"count":229,"type":23},80,[164],"This exploratory randomized controlled trial aims to investigate the immediate and long-term effects of exercise on sleep quality, emotional problems, executive function, and neurophysiological characteristics in college students with depressive symptoms. The study consists of two sequential phases: an acute exercise experiment followed by an 8-week exercise intervention. Participants will be randomly assigned to either an exercise intervention group or a control group. Psychological questionnaires, behavioral tasks, resting-state electroencephalography (EEG), brain functional connectivity, and event-related potentials (ERP) will be assessed to evaluate behavioral and neurophysiological changes before and after exercise. The study will further examine whether the immediate response to acute exercise predicts the effectiveness of the long-term intervention.",[29,233],"Sleep Disturbance",[235,236,29,237,238,239,240,241,242],"Exercise","College Students","Sleep Quality","Electroencephalography","Brain Functional Connectivity","Event-Related Potentials","Executive Function","Randomized Controlled Trial","2026-07-28",{"date":213,"type":39},{"date":246,"type":23},"2026-08-01",{"date":248,"type":23},"2026-12-30",{"name":250,"class":46},"Capital University of Physical Education and Sports, China",{"id":252,"slug":253,"hasResults":12,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":12,"sex":54,"minAge":258,"maxAge":259,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":98},"100622454","task-shifting-adapted-ipt-a-for-youth-suicide-prevention-100622454","NCT07383831","Task-Shifting Adapted IPT-A for Youth Suicide Prevention","Youth Mentor-Led Brief Interpersonal Psychotherapy for Youth Suicide Prevention","Inclusion Criteria:\n\n1. Parent consent\n2. Adolescent consent\n3. Enrolled in youth community centers\n4. Self-identified as Hispanic or Latine\n5. Between 12 and 17 years old.\n6. Scoring threshold for depression (4-9) as indicated in the PHQ-A.\n7. No current report of suicide ideation with plan or self-harming behaviors\n\nExclusion Criteria:\n\n1. Not consented to participate in the study\n2. Scoring 10 or higher in the PHQ-A, indicating depressive disorder\n3. Active suicide ideation (i.e., having thoughts of killing oneself, thinking about how in the past month).","12 Years","17 Years",{"count":261,"type":23},46,[164],"The goal of this randomized pragmatic clinical trial is to examine the feasibility, acceptability, and mechanisms of change of a brief adaptation of Interpersonal Psychotherapy for Adolescents (BIPT-A), adapted and task-shifted to lay providers (mentors, youth trusted adults) in youth community centers (YCCs) as an upstream approach to suicide.\n\nIt focuses on Hispanic adolescents ages 12-17 enrolled in these YCCs. The pragmatic clinical trial will evaluate the acceptability and feasibility of adapted IPT-A delivered by mentors in YCCs and whether adapted BIPT-A impacts mechanisms of change (depressive symptoms, belongingness, and burdensomeness or feeling like a burden to others).\n\nThe main questions to answer are:\n\n* Is adapted BIPT-A, when delivered by trained lay providers (youth mentors), feasible and acceptable in youth community centers?\n* Does adapted BIPT-A, delivered by lay providers, change key risk factors (i.e., key mechanisms: depressive symptoms, low belongingness, and perceived burdensomeness) associated with suicide ideation? The investigators will compare adolescents randomized to adapted BIPT-A (6 sessions) delivered by a trained youth mentor with those receiving usual services at the community center (one individual session focused on active listening).\n\nParticipants will:\n\n1. Be screened for subthreshold depression using the Patient Health Questionnaire Adolescent version (PHQ-A). Adolescent participants will be included if they score between 4 and 9 (mild depression). Participants with a PHQ-A score of 10 or higher (severe depression) will not be eligible and will be referred to a licensed mental health provider for appropriate care.\n2. Be randomized to adapted BIPT-A or usual care. Adolescent participants in the intervention arm will participate in 6 weekly, adapted BIPT-A sessions with a trained youth mentor. Intervention focuses on education, affect identification, and interpersonal skills.",[265,29,266],"Suicidal Ideation","Adolescent Mental Health","2026-07-27",{"date":243,"type":39},{"date":270,"type":23},"2026-10-01",{"date":272,"type":23},"2028-07-31",{"name":274,"class":46},"Boston College",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":54,"minAge":282,"maxAge":4,"enrollmentInfo":283,"targetDuration":4,"studyType":24,"phases":285,"briefSummary":286,"conditions":287,"keywords":290,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":98},"100610510","strength-and-pain-coping-through-resilience-and-knowledge-100610510","NCT07228520","Strength and Pain-Coping Through Resilience and Knowledge","SPARK","Inclusion Criteria:\n\n* Self-report pain \\>3 out of a 0 -10 scale that has lasted longer than 3 months and keeps subjects from doing at least one activity that subjects would like to do\n* Live in the community\n* Live in Central Maryland\n* Score a 5 or higher on the PHQ-9 (depression measure) at least two times during a two week period (screening call and then at first data collection visit)\n* Must be pre-frail (one or two criteria on frailty phenotype) or frail (three or more of the criteria on frailty phenotype)\n* One ADL or IADL limitation\n\nExclusion Criteria:\n\n* Hospitalized \\> 3 times in the last year\n* Participating in physical therapy\n* Have a terminal diagnosis (\\\u003C1 year expected survival)\n* \\> moderate intellectual impairment (5-7 errors) based on the Short Portable Mental Status Questionnaire (SPMSQ)\n* Unable to speak or understand English","50 Years",{"count":284,"type":23},100,[164],"Older adults who are 50 years of age and older with depressive symptoms, pain and difficulty with mobility will participate in the SPARK intervention study that includes 8 nurse visits in participants' homes to help participants with participants' pain and mood.",[288,29,289],"Pain","Aging",[291],"Older Adults","2026-07-21",{"date":294,"type":39},"2026-07-22",{"date":296,"type":39},"2026-06-01",{"date":298,"type":23},"2028-11-30",{"name":300,"class":46},"Johns Hopkins University",{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":307,"targetDuration":4,"studyType":24,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":317,"locationsCount":98},"100648217","morning-activation-to-improve-mood-after-stroke-100648217","NCT07719517","Morning Activation to Improve Mood After Stroke","Inclusion Criteria:\n\n* Age 18 years or older.\n* History of stroke at least 6 months before enrollment.\n* Patient Health Questionnaire-9 score of 10 or higher.\n* Difficulty getting started or engaging in activities in the morning.\n* Able to provide informed consent.\n\nExclusion Criteria:\n\n* Conditions that would interfere with study participation.\n* Neurological condition other than stroke.\n* Currently receiving psychological therapy for depression.\n* Significant cognitive impairment or dementia.\n* Current or past diagnosis of psychosis, bipolar disorder, or mania.\n* Hospitalization that would interfere with study participation.\n* Acute or significant suicidal ideation\n* Alcohol or substance use problems within the past month.\n* Use of antidepressant or anti-anxiety medication unless the dosage has been stable for at least 4 weeks and no changes are planned during the study.",{"count":22,"type":23},[164],"This pilot randomized controlled trial will evaluate the feasibility and preliminary effects of a six-week behavioral intervention designed to improve mood and daily functioning in adults who have experienced a stroke and report depressive symptoms and difficulty becoming engaged in activities after waking.\n\nParticipants will be randomly assigned to either the behavioral intervention or a health education program. Assessments will be completed before and immediately after the six-week program and will include questionnaires and seven-day monitoring of sleep, activity, and mood. The study will also examine feasibility indices such as participant retention, intervention attendance, acceptability, and preliminary changes in mood.",[311,29],"Stroke","2026-07-17",{"date":294,"type":39},{"date":315,"type":39},"2026-05-15",{"date":122,"type":23},{"name":318,"class":46},"The Hong Kong Polytechnic University",{"id":320,"slug":321,"hasResults":12,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":17,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":328,"briefSummary":329,"conditions":330,"keywords":334,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":352,"locationsCount":98},"100648020","sleep-more-stress-less-90-day-trial-of-neuralli-mood-100648020","NCT07717385","Sleep More, Stress Less: 90-Day Trial of Neuralli Mood","Effects of Neuralli Mood Probiotic Supplementation on Stress, Sleep Disturbance, Mood, and Burnout: A 90-Day Single-Arm Study","NM90","Inclusion Criteria:\n\n* Age 18 years or older and able to provide informed consent.\n* Generally healthy adult experiencing stress, occasional sleep disruption, low mood, anxiety symptoms, or work-related burnout.\n* Willing and able to take two capsules of Neuralli Mood daily for 90 days.\n* Willing and able to complete electronic baseline, follow-up, adherence, and safety assessments.\n* Has reliable access to the internet and an email-enabled device.\n\nExclusion Criteria:\n\n* Pregnant or nursing.\n* Known allergy or hypersensitivity to Neuralli Mood, probiotics, or any product ingredient.\n* Severe or unstable gastrointestinal disease, including a condition for which probiotic use may be inappropriate.\n* Immunocompromised status or current immunosuppressive therapy.\n* Severe or unstable mood disorder, acute psychiatric symptoms, or a current risk of harm to self or others.\n* A clinically significant sleep disorder for which participation or changes in symptoms should be managed by a healthcare professional.\n* Cognitive impairment or another condition that prevents informed consent or reliable completion of study procedures.\n* History of a severe allergic reaction when the investigator determines probiotic use may present an unacceptable risk.\n* Use of a medication or presence of a medical condition for which a healthcare professional advises against probiotic supplementation.\n* Any other circumstance that, in the investigator's judgment, makes participation inappropriate or unsafe.",{"count":284,"type":23},[164],"This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.",[331,233,332,29,333],"Psychological Stress","Anxiety Symptoms","Occupational Burnout",[335,336,337,338,339,340,341,342,343,344,345],"Neuralli Mood","Probiotic","Postbiotic","Psychobiotic","Gut-brain axis","Lactiplantibacillus plantarum PS128","Lacticaseibacillus paracasei PS23","Stress","Sleep","Burnout","Citizen science","2026-07-16",{"date":292,"type":39},{"date":349,"type":39},"2026-06-30",{"date":351,"type":23},"2027-09-28",{"name":353,"class":354},"Efforia, Inc","INDUSTRY",{"id":356,"slug":357,"hasResults":12,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":12,"sex":54,"minAge":362,"maxAge":4,"enrollmentInfo":363,"targetDuration":4,"studyType":24,"phases":365,"briefSummary":366,"conditions":367,"keywords":368,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":379,"leadSponsor":381,"locationsCount":4},"100647702","cognitive-stimulation-program-with-virtual-reality-for-older-adults-with-depressive-symptoms-100647702","NCT07710222","Cognitive Stimulation Program With Virtual Reality for Older Adults With Depressive Symptoms","Pilot Randomized Controlled Trial of a Cognitive Stimulation Program With Virtual Reality: Feasibility and Preliminary Efficacy in Older Adults With Depressive Symptoms","Inclusion Criteria:\n\n* Individuals aged 65 years or older attending Portuguese day care centers;\n* Presence of mild, moderate, or severe depressive symptomatology;\n* Language skills and visual acuity.\n\nExclusion Criteria:\n\n* Individuals presenting illiteracy and\u002For medical diagnosis of neurocognitive disorder or significant cognitive deficits (Mini-Mental State Examination)","65 Years",{"count":364,"type":23},60,[164],"The aim of this pilot RCT is the development, implementation, and evaluation of a cognitive stimulation program with virtual reality for individuals aged 65 or older who have depressive symptoms and attend Portuguese day centers. The program aims to promote their cognitive functioning, well-being and functionality, and to reduce their depressive symptoms. A pilot study of the program will be conducted to assess its feasibility and preliminary efficacy.",[29],[114,369,370,371,372,373,374,375],"Cognitive functioning","Well-being","Functionality","Mental health","Cognitive stimulation program","Virtual reality","Older adults","2026-07-13",{"date":312,"type":39},{"date":41,"type":23},{"date":380,"type":23},"2027-03",{"name":382,"class":46},"Grupo Lusófona",{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":54,"minAge":362,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":24,"phases":393,"briefSummary":394,"conditions":395,"keywords":396,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":98},"100646754","feasibility-and-effects-of-a-blended-baduanjin-exercise-and-green-tea-consumption-program-on-depressive-symptoms-gut-microbiota-and-quality-of-life-in-older-adults-100646754","NCT07687940","Feasibility and Effects of a Blended Baduanjin Exercise and Green Tea Consumption Program on Depressive Symptoms, Gut Microbiota and Quality of Life in Older Adults","Feasibility and Effects of a Blended Baduanjin Exercise and Green Tea Consumption Program on Depressive Symptoms, Gut Microbiota and Quality of Life in Older Adults: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. community-dwelling older adults aged 65 to 84 years, who are youngest-old and middle-old with relatively stable health status compared with oldest-old aged 85 years and above\n2. Scoring 5-15 using the Chinese version of Geriatric Depression Scale.\n3. Access the smartphone and internet through which the Hospital Authority (HA) HA Go mobile app.\n4. Pass the PAR-Q screening and no contraindications for physical exercise.\n5. No history of smoking.\n\nExclusion Criteria:\n\n1. suffer from cognitive impairment identified by the Chinese version of the Mini-Mental Status Examination (i.e., score \\\u003C 24).\n2. regularly consume tea or coffee (≥3 times\u002Fday, last for ≥6 months) as these habitual behaviors can contaminate the effects of tea consumption intervention per se.\n3. Individuals with contraindications for tea consumption, such as insomnia, anemia, neurasthenia, hyperthyroidism, digestive ulcers, etc.\n4. The concurrent use of sedative and tranquilizer medications, such as benzodiazepines and barbiturates.\n5. take warfarin;\n6. Participants are attending other health projects related to physical exercise and diet.","84 Years",{"count":392,"type":23},48,[164],"Depression is a common mental health issue in older adults, often manifesting as insomnia, low mood, vague somatic complaints, cognitive decline, and recurrent thoughts of death or suicide. Even subthreshold depressive symptoms in late life significantly impair quality of life. In Hong Kong, recent data show high prevalence of depressive symptoms among community-dwelling older adults (43.7% in men, 54.8% in women), underscoring the urgent public health and economic need for effective interventions.\n\nAlthough the previous evidence has shown that BDJ and GT consumption can improve depressive symptoms, gut microbiota, and QoL respectively, the feasibility and effect of the combination of two intervention approaches in older adults remain unclear. Therefore, the proposed study aims to (1) determine the feasibility of a 12-week blended BDJ and GT consumption program among Hong Kong community-dwelling older adults with depressive symptoms in a small-scale sample, and (2) examine the effects of the blended BDJ and GT consumption program on their depressive symptoms, gut-microbiota and QoL compared with that in the active control group.",[29],[397,398,399,400],"depressive symptoms","older adults","Baduanjin exercise","green tea",{"date":402,"type":39},"2026-07-07",{"date":404,"type":39},"2025-11-01",{"date":406,"type":23},"2027-04-30",{"name":408,"class":46},"Hong Kong Baptist University",{"id":410,"slug":411,"hasResults":12,"nctId":412,"briefTitle":413,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":17,"sex":54,"minAge":417,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":24,"phases":421,"briefSummary":422,"conditions":423,"keywords":426,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":98},"100609572","our-voices-matter-intervention-for-depression-in-youth-100609572","NCT07216326","Our Voices Matter: Intervention for Depression in Youth","Our Voices Matter: Racial Justice Activism Intervention to Address Structural Racism and Prevent Depression in Black and Latinx Youth","OVM","Inclusion Criteria:\n\n1. 15-20 years old\n2. Identify as Black and\u002F or Latinx\n3. Speak English\n\nExclusion Criteria:\n\n1. Younger than 15 years old, or older than 20 years old\n2. Unable to attend the in-person sessions\n3. Non-fluent English speaker\n4. Do not identify as Black or Latinx","15 Years","20 Years",{"count":420,"type":23},300,[164],"Over 15 million people participated in racial justice protests nationwide during 2020-2021 spotlighting activism as a collective tool against structural racism and discrimination (SRD). SRD manifests as policies and practices (e.g., redlining, voter suppression, mass incarceration) that produce hostile environments that contribute to psychological distress, elevated allostatic load, and an elevated risk for chronic diseases and premature death, concentrated within Black and Latinx populations. While the connection between SRD and health is well documented, few studies provide evidence on strategies to reduce SRD and mitigate consequences on psychological and physiological outcomes. Thus, there is a critical need to rigorously test interventions that improve the mental and physical health of Black and Latinx populations, beginning in adolescence. The study's specific aims are to 1) Determine whether a racial justice activism behavioral intervention prevents and reduces depressive symptoms in Black and Latinx adolescents and young adults and 2) Determine whether a racial justice activism behavioral intervention lowers allostatic load scores in Black and Latinx adolescents and young adults. To accomplish these aims, the team will conduct a stage II group-based, multi-component, and multilevel randomized behavioral clinical trial. The investigators will collect psychological and physiological measures at baseline, then at defined intervals for 2 years post the racial justice activism intervention.",[29,424,425],"Allostatic Load","Metabolic Syndrome",[427,428,429,430,397,431,432,433,434],"mental health","youth intervention","allostatic load","stress","depression","metabolic syndrome","prevention","inflammation","2026-06-12",{"date":437,"type":39},"2026-06-15",{"date":439,"type":39},"2025-06-06",{"date":441,"type":23},"2028-12-29",{"name":443,"class":46},"Ann & Robert H Lurie Children's Hospital of Chicago",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":54,"minAge":451,"maxAge":259,"enrollmentInfo":452,"targetDuration":4,"studyType":24,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":98},"100594524","improving-mood-for-adolescents-through-teaming-with-end-users-in-routine-care-the-imatter-project-100594524","NCT07020572","Improving Mood for Adolescents Through Teaming With End-Users in Routine Care (The iMATTER Project)","The iMATTER Project: Preventing Adolescent Depression in Pediatric Primary Care","Inclusion Criteria:\n\nFor Adolescent Participants\n\n1. Adolescents ages 13 to 17 years.\n2. Adolescents must be English-speaking.\n3. Legal guardian permission (informed consent) and child consent\u002Fassent.\n4. A score of 5-10 on the Patient Health Questionnaire 9-Item: Modified for Teens (PHQ-9-M) at the primary care well-visit.\n5. Access to a phone, computer, or other electronic device that could be used for study activities\n\nFor Legal guardian Participants\n\n1. Legal guardian of an adolescents ages 13 to 17 years who scored 5-10 on the PHQ-9-M at the primary care well-visit.\n2. Consent to participate.\n3. English-speaking.\n4. Access to a phone, computer, and\u002For tablet to complete remote evaluations.\n\nExclusion Criteria:\n\nExclusion criteria will be determined based on electronic health record (EHR) review, eligibility screening questions, the baseline evaluation, and any other interactions with the family.\n\n1. Suicidal ideation or behaviors reported on the PHQ-9-M at their well-visit (score of 1 or higher on item 9 \"In the past week, have you had thoughts that you would be better off dead, or of hurting yourself in some way?\" and\u002For yes to either of the supplemental questions which ask, \"Has there been a time in the past month when you have had serious thoughts about ending your life?\" and \"Have you ever, in your whole life, tried to kill yourself or made a suicide attempt?\") based on medical record review. For the PHQ-9-M administered at baseline, adolescents who mark yes to the supplemental item about serious suicidal ideation in the past month (\"Has there been a time in the past month when you have had serious thoughts about ending your life?\") will be excluded.\n2. Major medical illness, significant behavioral problems or intellectual or developmental disabilities that may interfere with the completion of all study procedures.\n3. Youth may be excluded on a case-by-case basis if the EHR review, eligibility screener, baseline evaluation, or other interactions with the family suggests that the group program would not be appropriate.","13 Years",{"count":453,"type":23},45,[164],"This pilot randomized controlled trial will examine the feasibility, acceptability and preliminary efficacy of an adolescent depression prevention program, Brief Interpersonal Psychotherapy-Adolescent Skills Training (B-IPT-AST), in primary care.",[29],{"date":437,"type":39},{"date":459,"type":39},"2025-03-20",{"date":461,"type":23},"2027-06",{"name":463,"class":46},"Children's Hospital of Philadelphia",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":471,"minAge":55,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":480,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":98},"100642691","phase-4-intranasal-esketamine-dexmedetomidine-combination-and-postpartum-depression-100642691","NCT07639099","Intranasal Esketamine-dexmedetomidine Combination and Postpartum Depression","Impact of Intranasal Esketamine-dexmedetomidine Combination on Postpartum Depression in Parturients With Prenatal Depressive Symptoms: a Randomized, Double-blind, and Placebo-controlled Trial","Inclusion Criteria:\n\n* Pregnant women aged ≥18 years who are preparing for childbirth;\n* Positive prenatal depression screening, defined as a Patient Health Questionnaire-9 (PHQ-9) score ≥5.\n\nExclusion Criteria:\n\n* History of schizophrenia or existence of communication barriers;\n* Severe obstetric complications, including severe preeclampsia, placenta accreta, HELLP syndrome, placenta previa, placental abruption, or ASA physical status classification \\>III;\n* Contraindications to ketamine\u002Fesketamine, including refractory hypertension, severe cardiovascular disease (NYHA class ≥III), or hyperthyroidism;\n* Contraindications to dexmedetomidine, including severe bradycardia (heart rate \\\u003C50 bpm), or second-degree or higher atrioventricular block;\n* Unsuitable for intranasal administration due to nasal cavity diseases (e.g., rhinitis, nasal polyps, or nasal congestion of any cause);\n* Refusal to participate in this study or concurrent participation in another clinical trial.","FEMALE",{"count":473,"type":23},164,[136],"Esketamine has rapid-onset antidepressant effects and may reduce postpartum depression in parturients with prenatal depressive symptoms. However, its adverse neuropsychiatric symptoms limits clinical application. Dexmedetomidine can alleviate these adverse symptoms and has independent antidepressant effect. This randomized, double-blind, placebo-controlled trial is designed to evaluate whether intranasal esketamine combined with dexmedetomidine can reduce the prevalence of postpartum depression in women with prenatal depressive symptoms.",[477,29,141,140,478,479],"Parturients","Intranasal Administration","Postpartum Depression",[477,481,141,140,482,483],"Prenatal depressive symptoms","Intranasal administration","Postpartum depression","2026-06-11",{"date":437,"type":39},{"date":487,"type":23},"2026-06",{"date":489,"type":23},"2029-12",{"name":152,"class":46},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":4,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":54,"minAge":362,"maxAge":498,"enrollmentInfo":499,"targetDuration":4,"studyType":24,"phases":500,"briefSummary":501,"conditions":502,"keywords":504,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":484,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":98},"100641674","rtms-combined-with-aerobic-exercise-for-older-adults-with-mild-cognitive-impairment-and-comorbid-depression-100641674","NCT07652775","rTMS Combined With Aerobic Exercise for Older Adults With Mild Cognitive Impairment and Comorbid Depression","Effects of Repetitive Transcranial Magnetic Stimulation Combined With Aerobic Exercise on Cognitive Function, Psychological Health, and Walking Performance in Older Adults With Mild Cognitive Impairment and Comorbid Depression: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 65 to 90 years.\n2. Diagnosed with mild cognitive impairment (MCI) according to established clinical criteria.\n3. Presence of depressive symptoms as determined by clinical assessment and Beck Depression Inventory-II (BDI-II).\n4. Able to communicate and follow study instructions.\n5. Able to ambulate independently with or without an assistive device.\n6. Able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Diagnosis of dementia.\n2. History of epilepsy or seizure disorder.\n3. Presence of metallic implants, pacemakers, cochlear implants, or other contraindications to transcranial magnetic stimulation.\n4. Major neurological disorders, including stroke, Parkinson's disease, traumatic brain injury, or other neurodegenerative diseases.\n5. Severe psychiatric disorders other than depression.\n6. Severe cardiovascular, musculoskeletal, or medical conditions that preclude participation in aerobic exercise.\n7. Severe visual or hearing impairments that interfere with cognitive assessment.\n8. Current participation in another intervention study.","90 Years",{"count":453,"type":23},[164],"This study aims to evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) and aerobic exercise on cognitive function and mental health in older adults with mild cognitive impairment (MCI) and comorbid depression. Forty-five participants will be randomly assigned to one of three groups: (1) rTMS alone, (2) rTMS combined with stationary cycling exercise, or (3) sham rTMS combined with stationary cycling exercise. Participants will receive 20 intervention sessions over a 5-week period (4 sessions per week). Outcomes, including cognitive function, depressive symptoms, sleep quality, life satisfaction, self-efficacy, and gait performance, will be assessed at baseline, immediately after completion of the 5-week intervention, and at a 1-month follow-up. The findings may contribute to the development of evidence-based, non-pharmacological interventions for improving cognitive and mental health outcomes in older adults with MCI and comorbid depression.",[503,29],"Mild Cognitive Impairment (MCI)",[505,506,507,508,509,291,510,511,512],"Repetitive Transcranial Magnetic Stimulation","Aerobic Exercise","Dual-Task Walking","Timed Up and Go","Cognitive Function","Life Satisfaction","Gait Performance","rTMS",{"date":193,"type":39},{"date":515,"type":39},"2026-03-03",{"date":517,"type":23},"2027-12-31",{"name":519,"class":46},"Cheng-Hsin General Hospital",{"id":521,"slug":522,"hasResults":12,"nctId":523,"briefTitle":524,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":18,"minAge":55,"maxAge":4,"enrollmentInfo":528,"targetDuration":4,"studyType":24,"phases":529,"briefSummary":530,"conditions":531,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":533,"lastUpdatePostDateStruct":534,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":538,"locationsCount":98},"100560199","michigan-mens-diabetes-project-iiimendiii-mind-and-motion-100560199","NCT06574035","Michigan Men's Diabetes Project III(MenDIII): Mind and Motion","Michigan Men's Diabetes Project 3 (MenD 3): Mind and Motion","MenDIII","Inclusion Criteria:\n\n* African American\u002FBlack males\n* age 18 years or older\n* ambulatory status\n* diagnosis of Type 2 Diabetes (T2D) for one year duration or longer\n* be under the care of a physician for their diabetes, self report an A1C of 7.0% or more in the last year\n* be willing to participate in study events (weekly physical activity, exercise and CBT sessions, group discussion sessions, and in-person health assessments)\n* have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet\u002Fphone\u002Fcomputer to complete study related tasks\n* live in the Wayne or Washtenaw County\\\\\n* have reliable transportation to in-person events\n\nExclusion Criteria:\n\n* stage 2 hypertension as defined by Joint National Committee (JNC) VIII\n* recent cardiac events\n* recent laser surgery for proliferative retinopathy\n* history of stroke\n* lower limb amputation\n* peripheral neuropathy\n* severe Chronic Obstructive Pulmonary Disease (COPD) (e.g., basal oxygen)\n* class III or IV heart failure\n* medical instability.\n\nPer American College of Sports Medicine (ACSM) guidelines, medical exclusion criteria will also include currently experiencing:\n\n* ongoing unstable angina\n* uncontrolled cardiac arrhythmia with hemodynamic compromise\n* active endocarditis\n* symptomatic severe aortic stenosis\n* acute myocarditis or pericarditis\n* acute aortic dissection\n* acute pulmonary embolism\n* pulmonary infarction\n* deep venous thrombosis\n* physical disability that precludes safe and adequate testing\n* chest discomfort with exertion\n* unreasonable breathlessness, or dizziness, fainting, or blackouts.\n\nAs part of the screening process, the investigators will ask the participant to self-report on these conditions. Participants who are currently receiving psychotherapy services for the treatment of depression from a mental health provider will be excluded. Participants who are currently receiving only medication management from a psychiatrist will be included.\n\nIf you are interested in the study, please complete our screening survey: https:\u002F\u002Fredcapproduction.umms.med.umich.edu\u002Fsurveys\u002F?s=JNPPEDANX7KLPPF9. Thank you so much!",{"count":229,"type":23},[164],"The Michigan Men's Diabetes Project III: Mind \\& Motion is an 7-month pilot randomized clinical trial. The investigators are looking to recruit 80 Black men with type 2 diabetes (T2D) (need to have diagnosis for at least one year) that are over the age of 18. Participants also must be under the care of a physician for their diabetes, self report an Hemoglobin A1c (A1C) of 7.0% or more in the last year, be willing to participate in study events (weekly physical activity, exercise and Cognitive Behavioral Therapy (CBT) sessions, group discussion sessions, and in-person health assessments), have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet\u002Fphone\u002Fcomputer to complete study related tasks, live in the Wayne or Washtenaw County, and have reliable transportation to in-person events. All participants will receive 8 hours\u002Fsessions of cognitive behavioral therapy. Participants randomized to the intervention arm will also receive 8 sessions of guided exercise at the same time. Following that they will also receive 8 group discussion sessions that will serve as on-going support. All sessions will be help via Zoom. Additionally, all participants will participate in The 4 health assessments will take place at baseline, 10 weeks, 18 weeks, and 30 weeks.",[532,29,114],"Diabetes Mellitus, Type 2","2026-06-10",{"date":435,"type":39},{"date":536,"type":39},"2025-01-13",{"date":41,"type":23},{"name":539,"class":46},"University of Michigan",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":546,"targetDuration":4,"studyType":24,"phases":548,"briefSummary":549,"conditions":550,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":556,"completionDateStruct":557,"leadSponsor":559,"locationsCount":4},"100540313","examining-the-health-effects-of-npower365-among-black-same-gender-loving-men-100540313","NCT06315218","Examining the Health Effects of NPOWER365 Among Black Same Gender Loving Men","Inclusion Criteria:\n\n1. Identify as Black or African American, regardless of ethnicity\n2. Identify as male, regardless of sex assigned at birth\n3. Are living with HIV and prescribed a daily ART regimen\n4. Are age ≥ 18;\n5. Have sex with men\n6. Own an internet-connected device (e.g., smartphone, tablet)\n7. Reside in the Atlanta-area EHE jurisdictions.\n\nExclusion Criteria:\n\n1. Lack of English fluency\n2. Past participation in the pilot.",{"count":547,"type":23},350,[164],"This research study aims to test the effectiveness, reach, and maintenance over time of the NPOWER365 HIV care intervention for Black men who have sex with men (BMSM) living with HIV. NPOWER365 is a BMSM community-developed multicomponent intervention that aims to: 1) Support daily health promotion via HIV health education and health maintenance reminders; 2) Foster positive social connections among BMSM via online moderated forums, interpersonal chats, and community calendars; 3) Connect clients to BMSM-affirming healthcare, including HIV treatment and mental healthcare; 4) Provide resources for housing, transportation, and other economic empowerment.",[551,552,553,29,332],"Sexual and Gender Minorities","Social Stigma","Medication Adherence","2026-06-08",{"date":533,"type":39},{"date":148,"type":23},{"date":558,"type":23},"2028-04",{"name":560,"class":46},"Rutgers, The State University of New Jersey",{"id":562,"slug":563,"hasResults":12,"nctId":564,"briefTitle":565,"officialTitle":566,"acronym":567,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":471,"minAge":55,"maxAge":4,"enrollmentInfo":569,"targetDuration":4,"studyType":24,"phases":570,"briefSummary":571,"conditions":572,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":580,"leadSponsor":582,"locationsCount":98},"100522645","cancer-pain-management-using-a-web-based-intervention-100522645","NCT06085313","Cancer Pain Management Using a Web-based Intervention","Cancer Pain Management: A Technology-Based Intervention for Asian American Breast Cancer Survivors","CAI","Inclusion Criteria:\n\n* women aged 18 years and older who identify as Chinese, Korean, or Japanese;\n* have had a breast cancer diagnosis in the past;\n* can read and write English, Mandarin (simplified or traditional), Korean, or Japanese;\n* have access to the internet through computers or mobile devices (mobile phones and tablets);\n* have experienced cancer pain during the past week (at least 1 on a scale from 0 to 5 \\[no symptom=0, mild symptom that does not bother=1, somewhat bothering symptom=2, moderate symptom=3, severe symptom=4, and worst possible symptom=5\\]);\n* have experienced depressive symptoms during the past two weeks (1 to 10 on the Patient Health Questionnaire) which is equivalent to the cut-point of minimal to moderate depression.\n\nExclusion Criteria:\n\n* less than 18 years old because their cancer experience would be different from that of adults.\n* Those who are in treatment or not in treatment, but who were diagnosed with breast cancer within the past five years, will be excluded.\n* Those who participated in the PI's pilot studies will be excluded.\n* The participants of R33 phase will exclude those in active depression treatment regardless of their level of depression.\n* Those without Internet access will be excluded, but those with Internet access through community\u002Fgroup computers will be included.",{"count":420,"type":23},[164],"This study is funded by the HEAL Initiative (https:\u002F\u002Fheal.nih.gov\u002F). Based on Preliminary Studies (PSs), the research team developed and pilot-tested an evidence-based Web App-based information and coaching\u002Fsupport program for cancer pain management (CAPA) that was culturally tailored to Asian American breast cancer survivors using multiple unique features. However, CAPA rarely considered depressive symptoms accompanying pain in its design or components, and PSs indicated the necessity of further individualization of the intervention components of CAPA due to diversities in the needs of ABD. The purpose of the proposed 2-phase study is to further develop CAPA with additional components for ABD and the individual optimization functionality (CAI) and to test the efficacy of CAI in improving cancer pain experience of ABD. The specific aims are to: a) develop and evaluate CAI through an expert review and a usability test (R61 phase); b) determine whether the intervention group (that uses CAI and usual care) will show significantly greater improvements than the active control group (that uses CAPA and usual care) in primary outcomes (cancer pain management and cancer pain experience including depressive symptoms) from baseline to post 1-month and post 3-months; c) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences) that mediate the intervention effects of CAI on the primary outcomes; and d) determine whether the effects of CAI on the primary outcomes are moderated by selected background, disease, genetic, and situational factors. This study is guided by the Bandura's Theory and the stress and coping framework by Lazarus and Folkman. The R61 phase includes: (a) the intervention development process, (b) a usability test among 15 ABD, 15 family members, and 15 community gatekeepers; and (c) an expert review among 10 experts in oncology. The R33 phase adopts a randomized repeated measures control group design among 300 ABD. Long-term goals are: (a) to extend and test CAI in various healthcare settings with diverse subgroups of ABD, (b) examine the costeffectiveness, sustainability, and scalability of CAI in the settings, and (c) translate CAI into health care for ABD.",[573,29,574],"Cancer of Breast","Cancer Pain","2026-06-06",{"date":577,"type":39},"2026-06-09",{"date":579,"type":39},"2024-02-20",{"date":581,"type":23},"2027-08-31",{"name":583,"class":46},"University of Texas at Austin",{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":24,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":606,"locationsCount":47},"100489874","rxwell-to-decrease-post-operative-opioid-use-in-total-knee-or-hip-arthroplasty-100489874","NCT05658796","RXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty","Telemedicine-delivered Digital Cognitive Behavioral Intervention to Decrease Post-operative Opioid Use Among Patients Undergoing Total Knee or Hip Arthroplasty","RxWell","Inclusion Criteria for the RXWell Study:\n\n* Adults \\>18 years\n* Scheduled for elective primary total knee arthroplasty (TKA) or hip replacement (THA) at the approved UPMC hospitals\n* Moderately high levels of mood disorder symptoms on validated PROMIS measures, defined as a T-score \\> or = to 60 on PROMIS Anxiety 4a short form and\u002For PROMIS Depression4a short form\n\nExclusion Criteria for the RXWell Study:\n\n* Patients undergoing non-elective surgery or secondary arthroplasty\n* Active delirium, neurocognitive impairment, or severe intellectual disability\n* No access to a smart device (phone or tablet)\n* Active alcoholism (defined as daily use of more than 1 liter of wine and \u002For 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)\n* Profound mood disorders requiring immediate intervention such as suicidal ideation, defined as a PROMIS Depression score of more than 70\n* A PROMIS Anxiety and\u002For Depression T-score \\>70, which corresponds to severe anxiety and depression.\n\n  * Patients needing immediate care will be referred to psychiatrists and primary team.","100 Years",{"count":594,"type":23},150,[164],"It is envisioned that multipronged benefits from this pilot work for the UPMC ISD and its members. It is expected the RxWell platform to provide the following benefits: expansion of the use of RxWell to all UPMC ISD members providing peri-operative mood management with advantage of improved peri-operative outcomes, improving saving for the UPMC ISD by hastening the recovery and decreased resource utilization, and addition to the high-value care of UPMC with this holistic approach to patient perioperative care",[598,142,29,114,599,600],"Mood Disorders","Anxiety Disorders","Anxiety Depression",{"date":602,"type":39},"2026-06-03",{"date":604,"type":39},"2023-01-27",{"date":248,"type":23},{"name":607,"class":46},"University of Pittsburgh",{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":24,"phases":618,"briefSummary":619,"conditions":620,"keywords":622,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":625,"lastUpdatePostDateStruct":626,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":98},"100467642","my-wellbeing-guide-a-novel-tool-for-managing-stress-and-improving-quality-of-life-100467642","NCT05369429","My Wellbeing Guide: A Novel Tool for Managing Stress and Improving Quality of Life","My Wellbeing Guide, Technology Facilitated Behavioral Intervention for Depression Among Diverse Patients in Ambulatory Oncology","R37","Inclusion Criteria:\n\na) having been reached out to by the study team for recruitment; (b) planned treatment and follow-up within the NM or UHealth healthcare system; (c) ≥ 18 years of age; (d) medical chart confirmed diagnosis of a solid or hematological malignancy; (e) elevated depressive symptoms on the PROMIS CAT (score \\> or = 55) within the last 3 months; (f) access to the internet; (g) willingness to be randomized; (h) able to read English or Spanish; (i) patients must have signed informed consent prior to registration on study\n\nExclusion Criteria:\n\nNote: The investigators will not include any vulnerable populations in this study.",{"count":617,"type":23},6516,[164],"The purpose of this study is to examine the implementation and effectiveness of the psychosocial eHealth intervention, My Wellbeing Guide, on the proposed primary outcome, depressive symptoms, in patients diagnosed with cancer who receive care at Northwestern Medicine and the University of Miami Health System. Eligible patients will be directly contacted by the study team for recruitment.\n\nThe intervention includes cognitive behavioral therapy management strategies for health-related stress in the form of animated videos, interactive activities, and written content. The intervention will be delivered via an online application over an 7-week period. Intervention participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.\n\nParticipants are randomized into either an intervention application (described above) or a control application (which will provide links to helpful resources for patients with cancer, such as the contact information for cancer support services at Northwestern University and the University of Miami, and the link to the National Cancer Institute website, and the American Cancer Society website.) Control participants will also complete four assessments: baseline (at the beginning of the research study), post-intervention (7 weeks after baseline), a 6-month follow-up, and a 12-month follow up.",[621,142,29],"Cancer",[623,624],"eHealth","Wellbeing","2026-05-28",{"date":296,"type":39},{"date":628,"type":39},"2022-12-02",{"date":630,"type":23},"2028-07-05",{"name":632,"class":46},"Northwestern University",{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":24,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":647,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":98},"100560871","impact-improving-proactive-approaches-for-cancer-survivors-mental-health-treatment-100560871","NCT06582784","IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)","Evaluation of a Proactive Identification and Digital Mental Health Intervention Approach to Address Unmet Psychosocial Needs of Individuals Living With Likely Incurable Cancer","IMPACT","Inclusion Criteria:\n\n* Age \\> 18 years\n* ILLIC (as determined during manual chart review)\n* Elevated depressive symptoms, defined as a score of ≥ 8 on the PHQ-9\n* Current owner of an iOS- or Android-compatible smartphone\n* Willingness to utilize a mobile app for the treatment of depressed mood (response of \"yes\" on yes\u002Fno item)\n* Have a valid e-mail address that is checked regularly or have regular access to text messages (to access follow-up assessments)\n* English language fluency\n\nExclusion Criteria:\n\n* Current suicidal ideation at study screening, defined as a response greater than or equal to 1 on item nine of the PHQ-9\n* Severe cognitive impairment that precludes completion of informed consent. For the purposes of assessing eligibility, this criterion is operationalized as:\n* Prior diagnosis of dementia, or Major Neurocognitive Disorder indicated either via self-report or in the EHR; or\n* Self-report of cognitive difficulties that impair functional independence",{"count":642,"type":23},279,[164],"The purpose of this research study is to evaluate a mobile application (app) for depression treatment called \"Moodivate\" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood.\n\nParticipants will be randomly assigned to either download the mobile app, \"Moodivate\", or not. Approximately 2\u002F3 of participants enrolled will receive the mobile app and the remaining 1\u002F3 will not.\n\nAll participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today.\n\nParticipation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and\u002For loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.",[114,29,621],"2026-05-19",{"date":648,"type":39},"2026-05-22",{"date":650,"type":39},"2024-10-28",{"date":652,"type":23},"2028-09-01",{"name":654,"class":46},"Medical University of South Carolina",{"id":656,"slug":657,"hasResults":12,"nctId":658,"briefTitle":659,"officialTitle":660,"acronym":4,"eligibilityCriteria":661,"healthyVolunteers":12,"sex":54,"minAge":662,"maxAge":4,"enrollmentInfo":663,"targetDuration":4,"studyType":24,"phases":664,"briefSummary":665,"conditions":666,"keywords":667,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":646,"lastUpdatePostDateStruct":672,"startDateStruct":673,"completionDateStruct":675,"leadSponsor":676,"locationsCount":98},"100497200","mobile-cbt-for-middle-aged-and-older-adults-100497200","NCT05754151","Mobile CBT for Middle Aged and Older Adults","Feasibility and Acceptability of a Mobile Cognitive Behavior Therapy App Targeting Depression and Anxiety in Older Adults","Inclusion Criteria:\n\n* Age 40 or older\n* Primary diagnosis of an anxiety or depressive disorder as determined by a clinical severity rating score of 4 or greater on the Anxiety Disorders Interview Schedule (ADIS).\n* Mini Mental Status Exam (MMSE) no more than 1 SD below the mean score for patient's age and education. If the remote version of the MMSE is used (e.g. during an evaluation on Zoom), the remote MMSE score will be converted to a standard MMSE score.\n* Access to an Apple iPhone, iPad, or Android device.\n\nExclusion Criteria:\n\n* Lifetime diagnosis of a bipolar or psychotic disorder.\n* Currently in cognitive behavior therapy.\n* Change in dose of a psychiatric medication in the past 12 weeks.\n* Initiation of psychotherapy in the past 12 weeks.\n* Intent or plan to attempt suicide.","40 Years",{"count":364,"type":23},[164],"This study aims to assess a mobile app called MAYA for use in middle-aged and older adults with anxiety or mood disorders. The MAYA app is designed to teach coping skills for anxiety and depression that are drawn from cognitive behavioral therapy. Participants will be asked to use the app for at least two days a week, 20 minutes on each day, for six weeks. Participants will have weekly check-ins as well as longer assessments at the beginning of the study, week 3, week 6 (end of treatment), and week 12 (follow up). During assessments, participants will answer brief questionnaires designed to assess their symptoms and impressions of the app. The main hypotheses of the study are that participants will complete most of the assigned sessions and that they will rate their impressions of the app highly. The secondary hypotheses are that symptoms of depression and anxiety will decrease with use of the MAYA app.",[210,29,114],[142,668,669,670,114,291,671],"CBT","Mobile Application","Cognitive Behavioral Therapy","Adults",{"date":648,"type":39},{"date":674,"type":39},"2023-06-16",{"date":461,"type":23},{"name":677,"class":46},"Weill Medical College of Cornell University"]